Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $25.20 USD
Change Today -0.40 / -1.56%
Volume 89.0K
SGNT On Other Exchanges
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

sagent pharmaceuticals inc (SGNT) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/14/14 - $33.60
52 Week Low
04/28/14 - $19.45
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

sagent pharmaceuticals inc (SGNT) Related Businessweek News

No Related Businessweek News Found

sagent pharmaceuticals inc (SGNT) Details

Sagent Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, sources, manufactures, and markets pharmaceutical products, principally injectable-based generic equivalents to branded products in North America. The company offers anti-infective products, such as Cefepime, an antibiotic used to treat infections of the urinary tract, and skin and skin structures, as well as moderate to severe pneumonia, intra-abdominal infections, and as empiric therapy for febrile neutropenic patients; and Levofloxacin, a fluoroquinolone antibacterial for the treatment of infections caused by susceptible bacteria, including nosocomial and community acquired pneumonia, sinusitis, chronic bronchitis, skin and skin structure infections, prostatitis, urinary tract infection, and pyelonephritis in adults of age 18 years or older. It also provides oncology products consisting of Leucovorin Calcium, a folic acid derivative used to prevent harmful effects of methotrexate when methotrexate is used to treat certain types of cancer; and Zoledronic Acid, a bisphosphonate given intravenously to prevent skeletal fractures in patients with cancers, such as multiple myeloma and prostate cancer, as well as for treating osteoporosis. In addition, the company offers critical care products comprising Heparin, an anticoagulant used to prevent and treat blood clotting during and after surgery and dialysis; and Propofol, a sedative used to induce and maintain general anesthesia during surgical procedures. As of December 31, 2014, its product portfolio included 54 marketed products. Sagent Pharmaceuticals, Inc. sells its products to hospitals, integrated delivery networks, and alternative site facilities through pharmaceutical wholesalers and specialty distributors. The company was formerly known as Sagent Holding Co. and changed its name to Sagent Pharmaceuticals, Inc. in April 2011. Sagent Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Schaumburg, Illinois.

466 Employees
Last Reported Date: 03/16/15
Founded in 2006

sagent pharmaceuticals inc (SGNT) Top Compensated Officers

President, Chief Legal Officer and Corporate ...
Total Annual Compensation: $312.7K
Founder and Director
Total Annual Compensation: $615.2K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $330.8K
Executive Vice President of National Accounts...
Total Annual Compensation: $287.4K
Compensation as of Fiscal Year 2013.

sagent pharmaceuticals inc (SGNT) Key Developments

Sagent Pharmaceuticals, Inc. Appoints Michael Logerfo as President

Sagent Pharmaceuticals, Inc. announced that its current EVP and Chief Legal Officer Michael Logerfo has been appointed President, effective April 15, 2015. In his new role as President, Mr. Logerfo will lead the company's Executive Management Committee, will continue to have primary responsibility over the company's strategic business development and legal functions, and will report to the Chairman of the Board. Mr. Logerfo has served as Executive Vice President, Chief Legal Officer and Corporate Secretary of Sagent since March 2012.

Shlomo Yanai Joins Sagent Pharmaceuticals, Inc.'s Board of Directors

Sagent Pharmaceuticals, Inc. announced that Shlomo Yanai has been appointed to its Board of Directors effective April 15, 2015. Mr. Yanai served as President and Chief Executive Officer of Teva Pharmaceutical Industries Ltd. from 2007 until 2012.

Sagent Pharmaceuticals, Inc. Announces the Launch of Vancomycin Hydrochloride for Injection, USP

Sagent Pharmaceuticals, Inc. announced the launch of Vancomycin Hydrochloride for Injection, USP, an anti-infective, in a 10 gram preservative-free pharmacy bulk package presentation. The Vancomycin 10 gram presentation is an addition to Sagent's Vancomycin 5 gram pharmacy bulk package offering. According to IMS, for the 12 months ending February 2015, the US market for Vancomycin approximated $196 million of which over 50% of the sales was pharmacy bulk package bottles. As with all products in Sagent's portfolio, Vancomycin features Sagent's PreventIV MeasuresS packaging and labeling, designed to help reduce medication errors.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SGNT:US $25.20 USD -0.40

SGNT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amphastar Pharmaceuticals Inc $15.25 USD -0.04
OraSure Technologies Inc $6.71 USD -0.09
Pfizer Ltd/India 2,150 INR 0.00
SciClone Pharmaceuticals Inc $8.96 USD -0.13
Sucampo Pharmaceuticals Inc $21.09 USD -0.31
View Industry Companies

Industry Analysis


Industry Average

Valuation SGNT Industry Range
Price/Earnings 20.7x
Price/Sales 2.8x
Price/Book 2.9x
Price/Cash Flow 20.3x
TEV/Sales 2.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SAGENT PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at